PubRank

Sehwan Han

Author PubWeight™ 11.27‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 c-myc amplification is associated with HER2 amplification and closely linked with cell proliferation in tissue microarray of nonselected breast cancers. Hum Pathol 2005 1.11
2 Comparing fluorescence in situ hybridization and chromogenic in situ hybridization methods to determine the HER2/neu status in primary breast carcinoma using tissue microarray. Mod Pathol 2003 1.04
3 Phase II randomized trial of neoadjuvant metformin plus letrozole versus placebo plus letrozole for estrogen receptor positive postmenopausal breast cancer (METEOR). BMC Cancer 2014 1.00
4 Comparative study of a single-incision laparoscopic and a conventional laparoscopic appendectomy for the treatment of acute appendicitis. J Korean Soc Coloproctol 2012 0.95
5 Analysis of the potent prognostic factors in luminal-type breast cancer. J Breast Cancer 2012 0.88
6 Silver-Enhanced In Situ Hybridization as an Alternative to Fluorescence In Situ Hybridization for Assaying HER2 Amplification in Clinical Breast Cancer. J Breast Cancer 2011 0.84
7 Survey of the application of the korean clinical practice recommendations on breast cancer treatment: the utility of the korean breast cancer society guidelines. J Breast Cancer 2012 0.83
8 Topoisomerase II-alpha gene deletion is not frequent as its amplification in breast cancer. Breast Cancer Res Treat 2006 0.83
9 Accelerated partial breast irradiation using multicatheter brachytherapy for select early-stage breast cancer: local control and toxicity. Radiat Oncol 2010 0.83
10 The prevalence and assessment of ErbB2-positive breast cancer in Asia: a literature survey. Cancer 2010 0.83
11 Comparison of Doxorubicin plus docetaxel neoadjuvant chemotherapy with Doxorubicin plus vinorelbine in primary breast cancer. J Breast Cancer 2011 0.81
12 Value of volume-based metabolic parameters for predicting survival in breast cancer patients treated with neoadjuvant chemotherapy. Medicine (Baltimore) 2016 0.75
13 Comparison of CVF (Cyclophosphamide+Vinorelbine+5-Fluorouracil) and CMF (Cyclophosphamide+Methotrexate+5-Fluorouracil) Adjuvant Chemotherapy in Early Breast Cancer. J Breast Cancer 2011 0.75